Skip to main content
. 2018 May 2;20:79. doi: 10.1186/s13075-018-1580-5

Fig. 1.

Fig. 1

Receiver operating characteristic curve of predicting primary nonadherence in methotrexate and biologics/tofacitinib test samples. Receiver operating characteristic curve for (left) methotrexate (n = 179, area under the curve (AUC) = 0.86) and (right) biologics/tofacitinib (n = 111, AUC = 0.78)